StockNews.AI
ORGS
StockNews.AI
166 days

Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies

1. Orgenesis acquires Neurocords’ assets for spinal cord injury therapies. 2. This acquisition enhances Orgenesis's reach in regenerative medicine.

2m saved
Insight
Article

FAQ

Why Bullish?

The acquisition aligns with Orgenesis's growth strategy, which historically boosts investor confidence. Past acquisitions have positively influenced ORGS's stock value.

How important is it?

The acquisition directly impacts ORGS's operational capabilities and market positioning, making it highly relevant to investors.

Why Long Term?

This strategic acquisition is expected to contribute to Orgenesis's growth over several years, similar to successful integrations in biotech.

Related Companies

CRSPEDITRGENNTLA
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced the acquisition of certain Neurocords LLC's ("Neurocords") assets related to advanced regenerative medicine therapies for spinal cord injuries (SCI).

Related News